Abstract
Cushing syndrome (CS) is characterized by increased morbidity and mortality compared to the general population. However, there are patients who have more clinical aggressive forms than others. Aim of the study is to evaluate whether the degree of hypercortisolism, defined by the number of times urinary free cortisol (UFC) levels exceed the upper limit of the normal range (ULN), is related to the worsening of phenotypic features, as well as metabolic and cardiovascular parameters, in a cohort of CS patients. A cross-sectional study was conducted on 192 patients with active CS, consecutively presenting at the outpatients’ clinic of the University Hospitals of Ancona, Naples, and Palermo. Patients were grouped into mild (UFC not exceeding twice the ULN), moderate (2–5 times the ULN), and severe (more than 5 times the ULN) hypercortisolism. Thirty-seven patients (19.3 %) had mild, 115 (59.8 %) moderate, and 40 (20.9 %) severe hypercortisolism. A significant trend of increase among the three groups was demonstrated for 8-, 16-, and 24-h serum cortisol levels (p < 0.001) and serum cortisol after low dose of dexamethasone suppression test (p = 0.001). No significant trend of increase was found regarding phenotype and comorbidities. The degree of hypercortisolism by itself does not appear to be a sufficient parameter to express the severity of CS. Therefore, estimating the severity of CS according to biochemical parameters remains a challenge, while the clinical phenotype and the associated comorbidities might be more useful to assessing the severity of the CS.

Similar content being viewed by others
References
X. Bertagna, L. Guignat, L. Groussin, J. Bertherat, Cushing’s disease. Best Pract. Res. Clin. Endocrinol. Metab. 23(5), 607–623 (2009)
J. Newell-Price, X. Bertagna, A.B. Grossman et al., Cushing’s syndrome. Lancet 367(9522), 1605–1617 (2006)
R. Pivonello, M.C. De Martino, M. De Leo, G. Lombardi, A. Colao, Cushing’s syndrome. Endocrinol. Metab. Clin. North Am. 37(1), 135–149 (2008)
R. Pivonello, M. De Leo, A. Cozzolino, A. Colao, The treatment of Cushing’s disease. Endocr. Rev. 36(4), 385–486 (2015)
J. Etxabe, J.A. Vazquez, Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin. Endocrinol. (Oxf) 40(4), 479–484 (1994)
J. Lindholm, S. Juul, J.O. Jørgensen, J. Astrup, P. Bjerre, Rasmussen U. Feldt et al., Incidence and late prognosis of Cushing’s syndrome: a population-based study. J. Clin. Endocrinol. Metab. 86(1), 117–123 (2001)
G. Arnaldi, T. Mancini, G. Tirabassi, L. Trementino, M. Boscaro, Advances in the epidemiology, pathogenesis, and management of Cushing’s syndrome complications. J. Endocrinol. Invest. 35(4), 434–448 (2012)
R. Pivonello, A. Faggiano, G. Lombardi, A. Colao, The metabolic syndrome and cardiovascular risk in Cushing’s syndrome. Endocrinol. Metab. Clin. North Am. 34(2), 327–329 (2005)
A. Faggiano, R. Pivonello, S. Spiezia, M.C. De Martino, M. Filippella, C. Di Somma et al., Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J. Clin. Endocrinol. Metab. 88(6), 2527–2533 (2003)
M.C. Amato, V. Guarnotta, C. Giordano, Body composition assessment for the definition of cardiometabolic risk. J. Endocrinol. Invest. 36(7), 537–543 (2013)
G. Arnaldi, T. Mancini, G. Tirabassi, L. Trementino, M. Boscaro, Advances in the epidemiology, pathogenesis, and management of Cushing’s syndrome complications. J. Endocrinol. Invest. 35(4), 434–448 (2012)
M.S. Lionakis, D.P. Kontoyiannis, Glucocorticoids and invasive fungal infections. Lancet 362(9398), 1828–1838 (2003)
D. Graversen, P. Vestergaard, K. Stochholm, C.H. Gravholt, J.O. Jørgensen, Mortality in Cushing’s syndrome: a systematic review and meta-analysis. Eur. J. Intern. Med. 23(3), 278–282 (2012)
R.N. Clayton, D. Raskauskiene, R.C. Reulen, P.W. Jones, Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J. Clin. Endocrinol. Metab. 96(3), 632–642 (2011)
Z.K. Hassan-Smith, M. Sherlock, R.C. Reulen, W. Arlt, J. Ayuk, A.A. Toogood, M.S. Cooper, A.P. Johnson, P.M. Stewart, Outcome of Cushing’s disease following transsphenoidal surgery in a single center over 20 years. J. Clin. Endocrinol. Metab. 97(4), 1194–1201 (2012)
G. Ntali, A. Asimakopoulou, T. Siamatras, J. Komninos, D. Vassiliadi, M. Tzanela, S. Tsagarakis, A.B. Grossman, J.A. Wass, N. Karavitaki, Mortality in Cushing’s syndrome: systematic analysis of a large series with prolonged follow-up. Eur. J. Endocrinol. 169(5), 715–723 (2013)
J.R. Lindsay, T. Nansel, S. Baid, J. Gumowski, L.K. Nieman, Longterm impaired quality of life in Cushing’s syndrome despite initial improvement after surgical remission. J. Clin. Endocrinol. Metab. 91(2), 447–453 (2006)
L. Trementino, G. Apolloni, C. Concettoni, M. Cardinaletti, M. Boscaro, G. Arnaldi, Association of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing’s syndrome. Eur. J. Endocrinol. 166(1), 35–42 (2012)
L.K. Nieman, B.M. Biller, J.W. Findling, M.H. Murad, J. Newell-Price, M.O. Savage, A. Tabarin, Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 100(8), 2807–2831 (2015)
L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart, V.M. Montori, The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 93(5), 1526–1540 (2008)
A. Colao, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, U. Schoenherr, D. Mills, L.R. Salgado, B.M. Biller, Pasireotide B2305 Study Group, A 12-month phase 3 study of pasireotide in Cushing’s disease. N. Engl. J. Med. 366(10), 914–924 (2012)
S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, K. Sen, L.R. Salgado, A. Colao, B.M. Biller, High variability in baseline urinary free cortisol values in patients with Cushing’s disease. Clin. Endocrinol. (Oxf). 80(2), 261–269 (2014)
J.A. Withworth, World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J. Hypertens. 21(11), 1983–1992 (2003)
D. Matthews, J. Hosker, A. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28(7), 412–419 (1985)
M. Matsuda, R. DeFronzo, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22(9), 1462–1470 (1999)
K.M. Utzschneider, R.L. Prigeon, M.V. Faulenbach, J. Tong, D.B. Carr, E.J. Boyko, D.L. Leonetti, M.J. McNeely, W.Y. Fujimoto, S.E. Kahn, Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 32(2), 335–341 (2009)
M.C. Amato, C. Giordano, M. Galia, A. Criscimanna, S. Vitabile, M. Midiri, A. Galluzzo, AlkaMesy Study Group, Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 33(4), 920–922 (2010)
Expert Panel on Detection, Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285(19), 2486–2497 (2001)
M.N. Starkman, B. Giordani, S. Berent, M.A. Schork, DE Schteingart, Elevated cortisol levels in Cushing’s disease are associated with cognitive decrements. Psychosomat. Med. 63(6), 985 (2001)
N. Sonino, G.A. Fava, A.R. Raffi, M. Boscaro, F. Fallo, Clinical correlates of major depression in Cushing’s disease. Psychopathology 31(6), 302–306 (1998)
R.C. Bakker, P.R. Gallas, J.A. Romijn, W.M. Wiersinga, Cushing’s syndrome complicated by multiple opportunistic infections. J. Endocrinol. Invest. 21(5), 329–333 (1998)
T. Reinehr, A. Kulle, B. Wolters, C. Knop, N. Lass, M. Welzel, P.M. Holterhus, Relationships between 24-hour urinary free cortisol concentrations and metabolic syndrome in obese children. J. Clin. Endocrinol. Metab. 99(7), 2391–2399 (2014)
N. Sonino, M. Boscaro, F. Fallo, G.A. Fava, A clinical index for rating severity in Cushing’s syndrome. Psychother. Psychosom. 69(4), 216–220 (2000)
J.G. Rosmalen, I.P. Kema, S. Wüst, C. van der Ley, S.T. Visser, H. Snieder, S.J. Bakker, 24 h urinary free cortisol in large-scale epidemiological studies: short-term and long-term stability and sources of variability. Psychoneuroendocrinology 47, 10–16 (2014)
T. Remer, C. Maser-Gluth, S.A. Wudy, Glucocorticoid measurements in health and disease metabolic implications and the potential of 24-h urine analyses. Mini Rev. Med. Chem. 8(2), 153–170 (2008)
M.M. Kushnir, A.L. Rockwood, G.J. Nelson, A.H. Terry, A.W. Meikle, Liquid chromatography tandem mass spectrometry analysis of urinary free cortisol. Clin. Chem. 49(6), 965–967 (2003)
M. Fenske, Urinary free cortisol and cortisone excretion in healthy individuals: influence of water loading. Steroids 71(11–12), 1014–1018 (2006)
K.C.A. Chan, L.C.W. Lit, E.L.K. Law, M.H.L. Tai, C.U. Yung, M.H.M. Chan, C.W.K. Lam, Diminished urinary free cortisol excretion in patients with moderate and severe renal impairment. Clin. Chem. 50(4), 757–759 (2004)
P.C. Elias, E.Z. Martinez, B.F. Barone, L.M. Mermejo, M. Castro, A.C. Moreira, Late-night salivary cortisol has a better performance than urinary free cortisol in the diagnosis of Cushing’s syndrome. J. Clin. Endocrinol. Metab. 99(6), 2045–2051 (2014)
P. Putignano, P. Toja, A. Dubini, F.P. Giraldi, S.M. Corsello, F. Cavagnini, Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for Cushing’s syndrome. J. Clin. Endocrinol. Metab. 88(9), 4153–4157 (2003)
C. Giordano, V. Guarnotta, R. Pivonello, M.C. Amato, C. Simeoli, A. Ciresi, A. Cozzolino, A. Colao, Is diabetes in Cushing’s syndrome only a consequence of hypercortisolism? Eur. J. Endocrinol. 170(2), 311–319 (2013)
A. Colao, R. Pivonello, S. Spiezia, A. Faggiano, D. Ferone, M. Filippella et al., Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J. Clin. Endocrinol. Metab. 84(8), 2664–2672 (1999)
M. Zilio, L. Mazzai, M.T. Sartori, M. Barbot, F. Ceccato, V. Daidone, A. Casonato, G. Saggiorato, F. Noventa, L. Trementino, P. Prandoni, M. Boscaro, G. Arnaldi, C. Scaroni. A venous thromboembolism risk assessment model for patients with Cushing’s syndrome. Endocrine 26, 1–11 (2015)
N.J. Sarlis, S.J. Chanock, L.K. Nieman, Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J. Clin. Endocrinol. Metab. 85(1), 42–47 (2000)
S. Takagi, A. Tanabe, M. Tsuiki, M. Naruse, K. Takano, Hypokalemia, diabetes mellitus, and hypercortisolemia are the major contributing factors to cardiac dysfunction in adrenal Cushing’s syndrome. Endocr. J. 56(8), 1009–1018 (2009)
I. Akaza, T. Yoshimoto, K. Tsuchiya, Y. Hirata, Endothelial dysfunction associated with hypercortisolism is reversible in Cushing’s syndrome. Endocr. J. 57(3), 245–252 (2010)
F. Fallo, G. Famoso, D. Capizzi, N. Sonino, F. Dassie, P. Maffei, C. Martini, A. Paoletta, S. Iliceto, F. Tona, Coronary microvascular function in patients with Cushing’s syndrome. Endocrine 43(1), 206–213 (2013)
A. Gungunes, M. Sahin, T. Demirci, B. Ucan, E. Cakir, M.S. Arslan, I.O. Unsal, B. Karbek, M. Calıskan, M. Ozbek, E. Cakal, T. Delibasi, Cushing’s syndrome in type 2 diabetes patients with poor glycemic control. Endocrine 47(3), 895–900 (2014)
P.M. Toja, G. Branzi, F. Ciambellotti, P. Radaelli, M. De Martin, L.M. Lonati, M. Scacchi, G. Parati, F. Cavagnini, F.P. Giraldi, Clinical relevance of cardiac structure and function abnormalities in patients with Cushing’s syndrome before and after cure. Clin. Endocrinol. (Oxf). 76(3), 332–338 (2012)
M.J. Barahona, E. Resmini, D. Viladés, G. Pons-Lladó, R. Leta, T. Puig, S.M. Webb, Coronary artery disease detected by multislice computed tomography in patients after long-term cure of Cushing’s syndrome. J. Clin. Endocrinol. Metab. 98(3), 1093–1099 (2013)
L. Manetti, G. Rossi, L. Grasso, V. Raffaelli, I. Scattina, S. Del Sarto, M. Cosottini, A. Iannelli, M. Gasperi, F. Bogazzi, E. Martino, Usefulness of salivary cortisol in the diagnosis of hypercortisolism: comparison with serum and urinary cortisol. Eur. J. Endocrinol. 168(3), 315–321 (2013)
N. Sonino, G.A. Fava, Psychiatric disorders associated with Cushing’s syndrome. Epidemiology, pathophysiology and treatment. CNS Drugs 15(5), 361–373 (2001)
L.D. Dorn, E.S. Burgess, T.C. Friedman, B. Dubbert, P.W. Gold, G.P. Chrousos, The longitudinal course of psychopathology in Cushing’s syndrome after correction of hypercortisolism. J. Clin. Endocrinol. Metab. 82(3), 912–919 (1997)
J.R. Seckl, B.R. Walker, 11b-Hydroxysteroid dehydrogenase type 1-a tissue-specific amplifier of glucocorticoid action. Endocrinology 142(4), 1371–1376 (2001)
V. Morelli, F. Donadio, C. Eller-Vainicher, V. Cirello, L. Olgiati, C. Savoca, E. Cairoli, A.S. Salcuni, P. Beck-Peccoz, I. Chiodini, Role of glucocorticoid receptor polymorphism in adrenal incidentalomas. Eur. J. Clin. Invest. 40(9), 803–811 (2010)
H. Masuzaki, J. Paterson, H. Shinyama, N.M. Morton, J.J. Mullins, J.R. Seckl, J.S. Flier, A transgenic model of visceral obesity and the metabolic syndrome. Science 294(5549), 2166–2170 (2001)
D.J. Wake, B.R. Walker, 11 beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Mol. Cell. Endocrinol. 215(1–2), 45–54 (2004)
N.M. Morton, M.C. Holmes, C. Fievet, B. Staels, A. Tailleux, J.J. Mullins, J.R. Seckl, Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J. Biol. Chem. 276(44), 41293–41300 (2001)
Acknowledgments
We would like to thank the RIMEDRI project for supporting V. Guarnotta.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Guarnotta, V., Amato, M.C., Pivonello, R. et al. The degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome. Endocrine 55, 564–572 (2017). https://doi.org/10.1007/s12020-016-0914-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-016-0914-9
Keywords
Profiles
- Giorgio Arnaldi View author profile